Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSABP B-41: Neoadjuvant AC-T with Trastuzumab, Lapatinib, or Both for HER2+ Breast Cancer
NCT00486668Phase 3Unknown
- Sponsor
- NSABP Foundation
- Start
- Jul 2007
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of lapatinib in HER2-positive breast cancer, sponsored by NSABP Foundation. Status: unknown.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00486668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00486668.